Smoking Cessation Strategies in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Maria A. Lopez-Oblio, MD, PhD; Gaurav Sharma, MD; Gagandeep Singh, MD; Justin James, BS; Kate J. Krause, MLS; Paul Cinciripini, PhD; Robert Volk, PhD; Maria Suarez-Almazor, MD, PhD;

Background
- >1% of the US population has been diagnosed with rheumatoid arthritis (RA)
- Up 30% of people with RA smoke in the US, which exceeds people without RA who do not smoke (15%)
- For people with RA, smoking has been associated with poor health outcomes, such as decreased response to treatment, increased cardiovascular risk, and decreased quality of life
- The benefits of smoking cessation are potentially numerous, however despite current guidelines on smoking cessation, approximately only 10% of rheumatology visits with patients who smoke include documentation of cessation counseling or follow-up advice.

Objective
To identify smoking cessation strategies and synthesize the reported cessation rates and the effects of the interventions effects in patients with RA

Methods
Information Sources
We searched 5 electronic databases (MEDLINE, EMBASE, Cochrane, CINAHL, and Web of Science) from inception until August 2020. Sources of gray literature (unpublished records) were searched through ClinicalTrials.gov. Reference lists of included articles were hand-searched to look for articles otherwise not found.

Eligibility Criteria
We included controlled trials and observational studies reporting the effects of interventions for smoking cessation in adult patients with RA in any setting.

Procedure
Screening, data collection, risk of bias assessment were done independently by two reviewers. Studies were using the risk of bias tool (RoB) and the risk of bias in non-randomized studies (ROBINS-I).

Results
Our search found 628 citations and found only 20 publications (17 studies) meeting our eligibility criteria (Figure 1).

Table 1 shows the study characteristics.

Table 1. Characteristics of included studies.

![Figure 1](Image)

Figure 1. Diagram of study selection.

![Figure 2](Image)

Figure 2. Types of intervention strategies in included studies.

Table 1 shows the study characteristics.

Table 1. Characteristics of included studies.

<table>
<thead>
<tr>
<th>Types of Publication</th>
<th>Location of Study</th>
<th>Study Design</th>
<th># of Centers</th>
<th>Setting</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstracts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full Text</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crocia, France, India, Ireland, Scotland, Spain, Sweden</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before &amp; After</td>
<td></td>
<td>Randomized Control Trial</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow-up Support Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intervention</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results
- Most non-randomized studies were assessed at critical risk of bias (Figure 3).
- 1 month to 2 years after the implementation of the cessation strategies, the pooled smoking cessation rate was 33% (Figure 4) and referrals to quit services increased from 4% to 23% (Table 2).

Conclusions
- Studies largely varied in patient characteristics, the interventions used, and their implementation structure.
- Only three studies were randomized clinical trials.
- The smoking cessation rate observed after the implementation of the reported strategies was lower than the published cessation rate of 62%.
- Additional controlled studies are needed to determine best practices for smoking cessation education, counsel, and pharmacological treatment offered to patients with RA.

Acknowledgements: The protocol of this systematic review was submitted to the International Prospective Register of Systematic Review (PROSPERO), the registration number is: CRD4202015287. This study was supported by the Tobacco Settlement Funds research resource program (Suarez-Almazor, PhD, Principal Investigator). Justin James was supported by a training grant from the National Cancer Institute (R25CA056452, Dr. Shine Chang, Principal Investigator). For further information, please contact Justin James at james002@citymail.cuny.edu.

<table>
<thead>
<tr>
<th>Secondary Outcomes</th>
<th># of Studies</th>
<th>Pooled Rates (OR)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-Intervention</td>
<td>Post-Intervention</td>
</tr>
<tr>
<td>Smoking Status</td>
<td>6</td>
<td>20% (19% to 21%)</td>
</tr>
<tr>
<td>Number of Cigarettes Smoked</td>
<td>3</td>
<td>11.5 (2.2 to 20.7)</td>
</tr>
<tr>
<td>Referral to Quit Lines for Smoking Cessation</td>
<td>4</td>
<td>4% (0% to 12%)</td>
</tr>
</tbody>
</table>

Table 2. Synthesis of results of secondary outcomes.

Disease Measures
- One study compared participants who quit smoking versus participants continuing smoking. The mean DAS28-CRP was higher in patients who continued smoking compared with patients who quit smoking (4.9 vs 2.9, respectively) (MD -2.0, 95% CI -2.3 to -1.7).
- Another study found that the Health Assessment Questionnaire (functional ability tool) score improved from 0.57 to 0.0 in the patients who quit versus 0.75 to 0.36 in patients who continued smoking (MD -0.26, 95% CI -0.84 to 0.32). Lower score indicates better functional ability.